Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap
Cardiovascular disease (CVD) remains the leading cause of death in women globally. Younger women (<55 years of age) who experience MI are less likely to receive guideline-directed medical therapy (GDMT), have a greater likelihood of readmission and have higher rates of mortality than similarly ag...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-11-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2021.24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850104251760508928 |
|---|---|
| author | Aarti Thakkar Anandita Agarwala Erin D Michos |
| author_facet | Aarti Thakkar Anandita Agarwala Erin D Michos |
| author_sort | Aarti Thakkar |
| collection | DOAJ |
| description | Cardiovascular disease (CVD) remains the leading cause of death in women globally. Younger women (<55 years of age) who experience MI are less likely to receive guideline-directed medical therapy (GDMT), have a greater likelihood of readmission and have higher rates of mortality than similarly aged men. Women have been under-represented in CVD clinical trials, which limits the generalisability of results into practice. Available evidence indicates that women derive a similar benefit as men from secondary prevention pharmacological therapies, such as statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, icosapent ethyl, antiplatelet therapy, sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Women are less likely to be enrolled in cardiac rehabilitation programs than men. Mitigating risk and improving outcomes is dependent on proper identification of CVD in women, using appropriate GDMT and continuing to promote lifestyle modifications. Future research directed at advancing our understanding of CVD in women will allow us to further develop and tailor CVD guidelines appropriate by sex and to close the gap between diagnoses, treatment and mortality. |
| format | Article |
| id | doaj-art-cf51f5baefdf4743a6c4acc3d74e9998 |
| institution | DOAJ |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2021-11-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-cf51f5baefdf4743a6c4acc3d74e99982025-08-20T02:39:22ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642021-11-011610.15420/ecr.2021.24Secondary Prevention of Cardiovascular Disease in Women: Closing the GapAarti Thakkar0Anandita Agarwala1Erin D Michos2Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USDivision of Cardiology, Baylor Scott and White Health Heart Hospital Baylor Plano, Plano, TX, USCiccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, MD, USCardiovascular disease (CVD) remains the leading cause of death in women globally. Younger women (<55 years of age) who experience MI are less likely to receive guideline-directed medical therapy (GDMT), have a greater likelihood of readmission and have higher rates of mortality than similarly aged men. Women have been under-represented in CVD clinical trials, which limits the generalisability of results into practice. Available evidence indicates that women derive a similar benefit as men from secondary prevention pharmacological therapies, such as statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, icosapent ethyl, antiplatelet therapy, sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists. Women are less likely to be enrolled in cardiac rehabilitation programs than men. Mitigating risk and improving outcomes is dependent on proper identification of CVD in women, using appropriate GDMT and continuing to promote lifestyle modifications. Future research directed at advancing our understanding of CVD in women will allow us to further develop and tailor CVD guidelines appropriate by sex and to close the gap between diagnoses, treatment and mortality.https://www.ecrjournal.com/articleindex/ecr.2021.24 |
| spellingShingle | Aarti Thakkar Anandita Agarwala Erin D Michos Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap European Cardiology Review |
| title | Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap |
| title_full | Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap |
| title_fullStr | Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap |
| title_full_unstemmed | Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap |
| title_short | Secondary Prevention of Cardiovascular Disease in Women: Closing the Gap |
| title_sort | secondary prevention of cardiovascular disease in women closing the gap |
| url | https://www.ecrjournal.com/articleindex/ecr.2021.24 |
| work_keys_str_mv | AT aartithakkar secondarypreventionofcardiovasculardiseaseinwomenclosingthegap AT ananditaagarwala secondarypreventionofcardiovasculardiseaseinwomenclosingthegap AT erindmichos secondarypreventionofcardiovasculardiseaseinwomenclosingthegap |